Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Biomedical Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9434 Online ISSN: 2049-9442
Journal Cover
July-August 2014 Volume 2 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
July-August 2014 Volume 2 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Changes in human sirtuin 6 gene promoter methylation during aging

  • Authors:
    • Kaniye Sahin
    • Sibel Yilmaz
    • Nermin Gozukirmizi
  • View Affiliations / Copyright

    Affiliations: Department of Molecular Biology and Genetics, Faculty of Science, Istanbul University, 34118 Vezneciler, Istanbul, Turkey
  • Pages: 574-578
    |
    Published online on: March 31, 2014
       https://doi.org/10.3892/br.2014.266
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Aging is a natural process during which changes at the cellular level increase death risk by developing susceptibility to a variety of diseases. Sirtuins have been shown to regulate lifespan in various organisms by deacetylating a number of important transcription factors. Of the 7 identified mammalian sirtuins (SIRT1‑7), SIRT6 depletion is associated with severe symptoms of premature aging. In this study, we investigated the association between human longevity and SIRT6 promoter methylation. Genomic DNA from blood samples of 55 individuals (34 females and 21 males) was examined to detect methylation levels by quantitative polymerase chain reaction analysis following bisulfite treatment. While the results indicated 43.21% methylation in the 9‑19 age group, this ratio was found to be increased up to 65.63% in the 20‑79 age group and decreased to 52.15% in the 80‑95 age group. Our results demonstrated that the SIRT6 gene is more active between 9‑19 and 80‑95 years compared to 20‑79 years.

Introduction

Sirtuins have attracted significant interest in aging studies over the last decade. Sirtuins have been shown to regulate important biological pathways in bacteria, archaea and eukaryotes by possessing NAD+-dependent histone deacetylase, mono-ribosyltransferase and tumor suppressor activity and by regulating gene expression or DNA repair (1–4). Of the 7 human sirtuins identified, the human SIRT6 gene is located on the minus strand of chromosome 19p13.3 and is available in a single copy encoding a 355-amino acid protein (39.1 kDa) (5). The SIRT6 protein localizes in the nucleus (6) and is required for DNA repair and maintenance of genomic stability in mammalian cells, integrating stress signaling to activate the DNA repair machinery in response to oxidative stress (7,8). Knockdown of SIRT6 in human cells renders them prone to chemically induced double-strand breaks (2,9). SIRT6 deficiency in mice has been shown to lead to the development of an acute degenerative aging-like phenotype (10). Although studies on SIRT6 knockout mice reported a strong correlation between premature aging and the absence of the SIRT6 protein (10), the reports on the overexpression of sirtuin homologues on various model organisms have been controversial, from no effect (11) to expansion of lifespan only in male mice (12). Analyses at the mRNA and protein level revealed SIRT6 expression in the majority of mouse and human tissues, with particularly high protein levels in the thymus, skeletal muscle and brain (13,14). However, there is no sufficient data on SIRT6 promoter methylation levels and their correlation with human longevity. To address this issue, we investigated the SIRT6 promoter methylation levels in 55 individuals of a wide age range by bisulfite-quantitative polymerase chain reaction (qPCR). The aim of this study was to elucidate the correlation between the percentage of SIRT6 promoter methylation and age and investigate whether it exhibits any association with longevity.

Materials and methods

Subjects and sample collection

This study included 55 individuals (34 females and 21 males), aged 9–95 years, divided into 8 age groups with 10-year intervals, with the exception of the 1st (9–19) and the 8th groups (80–95 years). Blood samples were collected at the Istanbul University Medico-Social Center, Turkey, with the written consent of the individuals who completed a form indicating their background regarding gender, age, inherited diseases, cancer, exposure to chemical or radioactive agents, permanent use of medicines, smoking habits and presence in the family of individuals aged >90 years. Genomic DNA was extracted from the blood samples using the High Pure PCR Template Preparation kit (Roche Diagnostics GmbH, Mannheim, Germany).

The procedures followed were in accordance with the current ethical standards.

Primer selection

The promoter sequence for SIRT6 was extracted and combined from Transcriptional Regulatory Element Database by Cold Spring Harbor Laboratory, Eukaryotic Promoter Database by the Swiss Institute of Bioinformatics and Promoter Controls by SwitchGear Genomics. The CpG islands were identified with the CpG Island Searcher (GC=66.2%; http://cpgislands.usc.edu). The primers were designed specifically for bisulfite-converted DNA with the MethPrimer (v1.1 beta) program (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi). The primer sequences were 5′-TTAATAAGGGAAATTTTATTGTTTT-3′ for the forward primer and 5′-CTAACCTCAATACCC CCTAATATTC-3′ for the reverse primer targeting a 212-bp region on the SIRT6 promoter.

Bisulfite-qPCR

A total of 500 ng of the extracted genomic DNAs were bisulfite-converted by the EZ DNA Methylation™ kit (D5002; Zymo Research, Irvine, CA, USA) according to the manufacturer’s recommendations. The converted DNA samples were dissolved in 15 μl elution buffer. The concentration of the eluted DNA was measured by NanoDrop (2000c; Thermo Scientific, Waltham, MA, USA) as RNA due to the single-stranded nature and uracil content of the bisulfite-converted DNA. The extracted DNAs were diluted to a concentration of 20 ng/μl. The specificity of the primers was confirmed by agarose gel electrophoresis following bisulfite-PCR using 20 ng sample DNA. To assess the methylation level of the region of interest, fully methylated (D5015; Zymo Research) and demethylated (EpiTect® Control DNA, 59665; Qiagen, Hilden, Germany) bisulfite-converted control DNAs were mixed accordingly to obtain 100, 80, 60, 20 and 10% methylated standards. A total of 10 ng of standards and sample DNAs were used for qPCR (CFX96; Bio-Rad, Hercules, CA, USA) along with 0.5 μM primers, 0.25 mM dNTP, 1× SYBR-Green I (Bioline, Taunton, MA, USA) and 0.5 unit of ZymoTaq™ DNA polymerase (E2002; Zymo Research) in a total volume of 10 μl. The PCR conditions were as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 30 sec, annealing at 57°C for 30 sec and extension with a plate reading step at 72°C for 1 min followed by a melting curve analysis step from 65°C to 95°C by 0.5°C increments for 5 sec. All the samples were examined in double replicates and the standard DNAs in triple replicates. The Ct values for the standard DNAs were used to generate a standard curve. The methylation levels of all the subjects were calculated according to the standard curve formula. The average methylation status of the age groups and standard deviations were calculated.

Statistical analysis

The significance levels of the probable association of SIRT6 promoter methylation rates with gender, smoking and longevity were calculated using non-parametric Kruskal-Wallis one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.

Results

Bisulfite-qPCR

The concentrations of the extracted bisulfite-converted DNAs were measured to be 23.5–39.1 ng/μl and were diluted to 20 ng/μl. Following qPCR analysis, a standard curve was generated with the mean Ct values of the standards (Figs. 1 and 2). The SIRT6 promoter methylation levels of the subjects were calculated using their mean Ct values according to the standard curve formula: y = 0.1493x + 20.966

Figure 1

Amplification curve of the standards. Methylated standards (100, 80, 60, 20 and 10%) were used to assess the methylation levels of the samples. RFU, relative fluorescence units.

Figure 2

Standard methylation curve. The methylation curve was established by the standards (R2=0.9335).

The methylation levels and information on the subjects are presented in Table I.

Table I

Evaluation of the subjects.

Table I

Evaluation of the subjects.

Group no.Subject no.GenderSIRT6 promoter methylation (%)Age (years)Permanent medical treatment
+
Smoking habit
+
Extended longevity in the family
+
11-1Male66.749X
1-2Female65.259
2-1Male37.1811X
2-2Female46.2215X
2-3Male15.6315
2-4Female15.1017XX
2-5Female56.3419X
23-1Male62.7620
3-2Male53.9724
3-3Female78.0822X
3-4Male67.4024XX
3-5Female52.5722X
3-6Male59.4023X
3-7Female68.0020X
3-8Female63.7524X
3-9Male63.3924XX
34-1Male70.4232X
4-2Female59.4632XX
4-3Male62.3832X
4-4Female67.0232XXX
4-5Male71.4132X
4-6Male65.4332XX
4-7Female65.1333XX
4-8Female64.8534X
4-9Female61.0334
45-1Female45.9847X
5-2Female52.2245X
5-3Male65.7844
5-4Female78.1942X
5-5Female69.9845X
5-6Female77.3042
5-7Male73.9641XX
56-1Female67.9151X
6-2Female59.9651X
6-3Female74.6452XX
6-4Female68.5552XXX
6-5Male76.3653X
6-6Female68.2659X
67-1Female65.1963X
7-2Female75.6065X
7-3Male74.3167X
7-4Male72.9965XX
7-5Female56.7064XX
78-1Female64.0571XX
8-2Female62.3072X
8-3Female60.0573XX
8-4Female52.2275X
8-5Male65.5175X
89-1Male39.8780X
9-2Female31.5183XX
9-3Female39.1183X
9-4Male35.1788XX
9-5Female86.3988X
10-1Female66.2591XX
10-2Male66.7495XX

[i] SIRT6, sirtuin 6 gene.

The average methylation percentages in different age groups were calculated. The methylation of the SIRT6 promoter was found to be 43.21% in the 9–19 age group, an average of 65.63% in the 20–79 age group and 52.15% in the 80–95 age group (Fig. 3).

Figure 3

Average methylation percentage in different age groups. Age group 1, 9–19; 2, 20–29; 3, 30–39; 4, 40–49; 5, 50–59; 6, 60–69; 7, 70–79; and 8, 80–95 years.

Statistical analysis

The Kruskal-Wallis test confirmed that the methylation differences between at least two age groups were significant (P=0.011). However, we were unable to identify a significant correlation between methylation status and gender (P=0.806), smoking (P=0.180), family history of cancer (P=0.504), exposure to chemical or radioactive agents (P=0.085), or extended longevity in the family (P=0.556).

Discussion

In this study, we determined the promoter methylation status of the human SIRT6 gene in lymphocytes of 55 subjects aged 9–95 years. Our data indicated that the promoter was highly methylated between 20 and 79 years. The regulatory association of methylation of CpG islands in the repression of gene expression was previously established (15). However, there was no significant correlation with longevity, gender, permanent medical treatment or smoking observed in our study. These results are consistent with those reported by Michishita et al (16), who demonstrated that the overexpression of SIRT6 in fibroblasts or epithelial cells was not associated with a lifespan extension compared to normal cells.

There are currently no available data on the methylation levels of the human SIRT6 promoter. However, Ren et al (17) demonstrated that SIRT6 mRNA levels in porcine brain decreased with age, which is an indicator of a possible increase in promoter methylation. By contrast, SIRT6 protein levels were found to be increased during aging in diabetic mice (18) and following exercise in young and older mice (19). There is also accumulating evidence that SIRT6 is regulated in a circadian fashion. It was proven that NAD+ levels and SIRT1 activity change according to a circadian rhythm (20,21). SIRT6 is a NAD+-dependent enzyme and is also positively regulated by SIRT1 (22). Therefore, it is possible that SIRT6 is also regulated in a circadian manner. Marquardt et al (23) demonstrated that changing the SIRT6 expression in mice also changed the expression of certain genes related to the circadian rhythm.

SIRT6 is a chromatin-associated protein expressed in the majority of tissues. To gain insight into SIRT6 function, a characterization of the subcellular and tissue distribution patterns of its expression is required. Apart from age, SIRT6 expression or activity may change during the day, before and after meals or before and after exercise (19,24,25). In summary, we demonstrated that promoter methylation of human SIRT6 is detectable by bisulfite-qPCR, but there was no correlation with longevity. Further research and clinical studies are required to fully elucidate the mechanisms underlying the process of aging.

Acknowledgements

This study was supported by the Istanbul University Department of Scientific Research Project (grant no. 21953).

References

1 

Kawahara TL, Michishita E, Adler AS, et al: SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell. 136:62–74. 2009. View Article : Google Scholar : PubMed/NCBI

2 

McCord RA, Michishita E, Hong T, et al: SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging (Albany NY). 1:109–121. 2009.PubMed/NCBI

3 

Michishita E, McCord RA, Berber E, et al: SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 452:492–496. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Sebastian C, Zwaans BM, Silberman DM, et al: The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI

5 

Mahlknecht U, Ho AD and Voelter-Mahlknecht S: Chromosomal organization and fluorescence in situ hybridization of the human sirtuin 6 gene. Int J Oncol. 28:447–456. 2006.PubMed/NCBI

6 

Tennen RI, Berber E and Chua KF: Functional dissection of SIRT6: identification of domains that regulate histone deacetylase activity and chromatin localization. Mech Ageing Dev. 131:185–192. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Mao Z, Hine C, Tian X, et al: SIRT6 promotes DNA repair under stress by activating PARP1. Science. 332:1443–1446. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Cardus A, Uryga AK, Walters G and Erusalimsky JD: SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence. Cardiovasc Res. 97:571–579. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Kaidi A, Weinert BT, Choudhary C and Jackson SP: Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science. 329:1348–1353. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Mostoslavsky R, Chua KF, Lombard DB, et al: Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 124:315–329. 2006. View Article : Google Scholar : PubMed/NCBI

11 

Burnett C, Valentini S, Cabreiro F, et al: Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature. 477:482–485. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Kanfi Y, Naiman S, Amir G, et al: The sirtuin SIRT6 regulates lifespan in male mice. Nature. 483:218–221. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Moschen AR, Wieser V, Gerner RR, et al: Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J Hepatol. 59:1315–1322. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Lee OH, Kim J, Kim JM, et al: Decreased expression of sirtuin 6 is associated with release of high mobility group box-1 after cerebral ischemia. Biochem Biophys Res Commun. 438:388–394. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Kundu TK and Rao MR: CpG islands in chromatin organization and gene expression. J Biochem. 125:217–222. 1999. View Article : Google Scholar : PubMed/NCBI

16 

Michishita E, Park JY, Burneskis JM, Barrett JC and Horikawa I: Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 16:4623–4635. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Ren Y, Shan TZ, Zhu LN, Wu T, Guo J and Wang YZ: Effect of breed on the expression of sirtuins (Sirt1–7 and antioxidant capacity in porcine brain. Animal. 7:1994–1998. 2013.

18 

Ghiraldini FG, Crispim AC and Mello ML: Effects of hyperglycemia and aging on nuclear sirtuins and DNA damage of mouse hepatocytes. Mol Biol Cell. 24:2467–2476. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Koltai E, Szabo Z, Atalay M, et al: Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech Ageing Dev. 131:21–28. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Nakahata Y, Sahar S, Astarita G, Kaluzova M and Sassone-Corsi P: Circadian control of the NAD+salvage pathway by CLOCK-SIRT1. Science. 324:654–657. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Bellet MM and Sassone-Corsi P: Mammalian circadian clock and metabolism - the epigenetic link. J Cell Sci. 123:3837–3848. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Kim HS, Xiao C, Wang RH, et al: Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 12:224–236. 2010. View Article : Google Scholar : PubMed/NCBI

23 

Marquardt JU, Fischer K, Baus K, et al: Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Ban N, Ozawa Y, Inaba T, Miyake S, Watanabe M, Shinmura K and Tsubota K: Light-dark condition regulates sirtuin mRNA levels in the retina. Exp Gerontol. 48:1212–1217. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Kanfi Y, Shalman R, Peshti V, et al: Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett. 582:543–548. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Sahin K, Yilmaz S and Gozukirmizi N: Changes in human sirtuin 6 gene promoter methylation during aging. Biomed Rep 2: 574-578, 2014.
APA
Sahin, K., Yilmaz, S., & Gozukirmizi, N. (2014). Changes in human sirtuin 6 gene promoter methylation during aging. Biomedical Reports, 2, 574-578. https://doi.org/10.3892/br.2014.266
MLA
Sahin, K., Yilmaz, S., Gozukirmizi, N."Changes in human sirtuin 6 gene promoter methylation during aging". Biomedical Reports 2.4 (2014): 574-578.
Chicago
Sahin, K., Yilmaz, S., Gozukirmizi, N."Changes in human sirtuin 6 gene promoter methylation during aging". Biomedical Reports 2, no. 4 (2014): 574-578. https://doi.org/10.3892/br.2014.266
Copy and paste a formatted citation
x
Spandidos Publications style
Sahin K, Yilmaz S and Gozukirmizi N: Changes in human sirtuin 6 gene promoter methylation during aging. Biomed Rep 2: 574-578, 2014.
APA
Sahin, K., Yilmaz, S., & Gozukirmizi, N. (2014). Changes in human sirtuin 6 gene promoter methylation during aging. Biomedical Reports, 2, 574-578. https://doi.org/10.3892/br.2014.266
MLA
Sahin, K., Yilmaz, S., Gozukirmizi, N."Changes in human sirtuin 6 gene promoter methylation during aging". Biomedical Reports 2.4 (2014): 574-578.
Chicago
Sahin, K., Yilmaz, S., Gozukirmizi, N."Changes in human sirtuin 6 gene promoter methylation during aging". Biomedical Reports 2, no. 4 (2014): 574-578. https://doi.org/10.3892/br.2014.266
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team